UBS lifts AbbVie target as focus expands beyond immunology drugs

AbbVie

09/10/2026 15:53

** UBS raises AbbVie ABBV.N PT to $275 from $260
** Says investor focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in the immunology franchise; adds momentum is continuing elsewhere in the pipeline 
** Expects a solid Q3 from Skyrizi and Rinvoq, with sales of $5.7 billion and $2.7 billion, respectively
** Highlights upcoming data for Skyrizi combination therapies in Crohn's disease and ulcerative colitis, with mid-stage data due later this month
** Sees inflammatory skin condition drug lutikizumab as a potential $1 billion to $2 billion opportunity; indicates Rinvoq could be a $500 million-plus sales opportunity
** Cites positive late-stage data for cancer drugs Epkinly and etentamig, and the recent launch of Parkinson's treatment tavapadon
** Estimates Q3 EPS of $3.76, within AbbVie's forecast range of $3.73 to $3.77 
** Including session moves, stock up 21% YTD

(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))